Erratum: Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation (Proceedings of the National Academy of Sciences of the United States of America (2012) 109, 12, (4598-4603) DOI: 10.1073/pnas.1118104109);Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 12, 2012, Pages 4598-4603

  O'Boyle, Graeme ^a   Fox, Christopher R J ^a   Walden, Hannah R ^b   Willet, Joseph D P ^a   Mavin, Emily R ^a   Hine, Dominic W ^a   Palmer, Jeremy M ^a   Barker, Catriona E ^a   Lamb, Christopher A ^a   Ali, Simi ^a   Kirby, John A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

Author keywords

Autoimmune; Chemotaxis; Humanization; PS372424

Indexed keywords

CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; PS 372424; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MIGRATION; CHEMOTAXIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 84858695989     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205285109     Document Type: Erratum

References (40)

1. Pease JE, Williams TJ (2006) The attraction of chemokines as a target for specific anti-inflammatory therapy. Br J Pharmacol 147(Suppl 1):S212-S221. (Pubitemid 43077279)
2. Horuk R (2009) Chemokine receptor antagonists: Overcoming developmental hurdles. Nat Rev Drug Discov 8:23-33.
3. Schall TJ, Proudfoot AE (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 11:355-363.
4. Proudfoot AE, Power CA, Schwarz MK (2010) Anti-chemokine small molecule drugs: A promising future? Expert Opin Investig Drugs 19:345-355.
5. Ali S, O'Boyle G, Mellor P, Kirby JA (2007) An apparent paradox: Chemokine receptor agonists can be used for anti-inflammatory therapy. Mol Immunol 44:1477-1482. (Pubitemid 44792739)
6. Kramp BK, Sarabi A, Koenen RR, Weber C (2011) Heterophilic chemokine receptor interactions in chemokine signaling and biology. Exp Cell Res 317:655-663.
7. Bromley SK, Mempel TR, Luster AD (2008) Orchestrating the orchestrators: Chemokines in control of T cell traffic. Nat Immunol 9:970-980.
8. Iwamoto T, Okamoto H, Toyama Y, Momohara S (2008) Molecular aspects of rheumatoid arthritis: Chemokines in the joints of patients. FEBS J 275:4448-4455.
9. Newton P, O'Boyle G, Jenkins Y, Ali S, Kirby JA (2009) T cell extravasation: Demonstration of synergy between activation of CXCR3 and the T cell receptor. Mol Immunol 47:485-492.
10. Flier J, et al. (2001) Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 194:398-405. (Pubitemid 32782663)
11. Sørensen TL, et al. (1999) Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103:807-815. (Pubitemid 29152626)
12. Schroepf S, et al. (2010) Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 16:1882-1890.
13. Katschke KJ, Jr., et al. (2001) Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 44:1022-1032.
14. Rosenblum JM, et al. (2009) CXCR3 antagonism impairs the development of donor-reactive, IFN-gamma-producing effectors and prolongs allograft survival. Transplantation 87:360-369.
15. Proudfoot AE, Power CA, Schwarz MK (2010) Anti-chemokine small molecule drugs: A promising future? Expert Opin Investig Drugs 19:345-355.
16. Ali S, et al. (2005) A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J Immunol 175:1257-1266. (Pubitemid 41095015)
17. O'Boyle G, Mellor P, Kirby JA, Ali S (2009) Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB J 23:3906-3916.
18. Severin IC, et al. (2010) Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans. J Biol Chem 285:17713-17724.
19. Stroke IL, et al. (2006) Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries. Biochem Biophys Res Commun 349:221-228. (Pubitemid 44331785)
20. Jopling LA, et al. (2007) Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay. Br J Pharmacol 152:1260-1271. (Pubitemid 350242445)
21. Batard P, et al. (2002) Use of phycoerythrin and allophycocyanin for fluorescence resonance energy transfer analyzed by flow cytometry: Advantages and limitations. Cytometry 48:97-105. (Pubitemid 34591922)
22. Anghelescu AV, et al. (2008) Technique for generating three-dimensional alignments of multiple ligands from one-dimensional alignments. J Chem Inf Model 48:1041-1054.
23. O'Boyle G, Brain JG, Kirby JA, Ali S (2007) Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2. Mol Immunol 44:1944-1953.
24. Meiser A, et al. (2008) The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. J Immunol 180:6713-6724.
25. Nedjai B, et al. (2011) Small-molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Br J Pharmacol, 10.1111/j.1476-5382.2011.01660.x.
26. Wang XN, et al. (2009) Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming. Transplantation 88:188-197.
27. Hoerning A, et al. (2011) Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3. Eur J Immunol 41:2291-2302.
28. Baribaud F, et al. (2001) Antigenically distinct conformations of CXCR4. J Virol 75:8957-8967. (Pubitemid 32851900)
29. Pearson T, et al. (2008) Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: A radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol 154:270-284.
30. Sprent J, Surh CD (2011) Normal T cell homeostasis: The conversion of naive cells into memory-phenotype cells. Nat Immunol 12:478-484.
31. Heise CE, et al. (2005) Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther 313:1263-1271. (Pubitemid 40727031)
32. Stewart DA, Smith C, MacFarland R, Calandra G (2009) Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 15:39-46.
33. Sedgwick AD, Sin YM, Edwards JC, Willoughby DA (1983) Increased inflammatory reactivity in newly formed lining tissue. J Pathol 141:483-495. (Pubitemid 14216382)
34. van Wanrooij EJ, et al. (2008) CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 28:251-257.
35. Hüttenrauch F, Pollok-Kopp B, Oppermann M (2005) G protein-coupled receptor kinases promote phosphorylation and beta-arrestin-mediated internalization of CCR5 homo- and hetero-oligomers. J Biol Chem 280:37503-37515. (Pubitemid 41642359)
36. Ward NE, O'Brian CA (1992) Kinetic analysis of protein kinase C inhibition by staurosporine: Evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates. Mol Pharmacol 41:387-392.
37. Wijtmans M, et al. (2011) CXCR3 antagonists: Quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors. Bioorg Med Chem 19:3384-3393.
38. Edgell CJ, et al. (1990) Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926. In Vitro Cell Dev Biol 26:1167-1172.
39. Mellor P, et al. (2007) Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer 97:761-768. (Pubitemid 47396282)
40. Kumar A, et al. (2006) CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity 25:213-224. (Pubitemid 44224150)